Candel Therapeutics (CADL) announced the appointment of Bali Pulendran, Ph.D. to Candel’s Research Advisory Board, RAB. Dr. Pulendran is the Violetta L. Horton Professor at Stanford University School of Medicine and Director of the Institute for Immunity, Transplantation and Infection at Stanford University and a Fellow at ChEM-H
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics: Hold Rating Amid Promising Developments and Financial Uncertainty
- Candel Therapeutics Secures $130M Loan for Trials
- Candel Therapeutics enters into $130M term loan facility
- Candel Therapeutics announces interim data from phase 1b CAN-3110 trial
- Trinity Capital provides $130M in growth capital to Candel Therapeutics